Abstract
Several new sustained-release formulations of theophylline were developed and their sustained-release performance was evaluated in a comparative pharmacokinetic analysis. These new formulations, Theo-Dur, Theotrim and aminophylline were administered to 5 dogs and 6 healthy volunteers. Plasma levels of theophylline were determined by an HPLC assay. The absorption profiles of the various formulations were analyzed pharmacokinetically, using the Wagner-Nelson procedure. Two new formulations, Theotrim and Theo-Dur demonstrated very good sustained-release performance in humans and dogs. One formulation (T-2-A) showed incomplete absorption in both species, and its bioavailability relative to aminophylline was about 65% in humans and 78% in dogs. These results were also confirmed by the Wagner-Nelson Procedure. In this study the dog was found to be a good animal model as far as the rate and extent of absorption of the various tested theophylline formulations were concerned; the dog may be useful in primary screening of new formulations from this series.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
